» Rosetta Genomics - Mesothelioma News

Offering hope, help, and support to mesothelioma patients and their families.

Get Help Now.

News Categories
- 9/11 Asbestos Risks (4)
- Asbestos & Mesothelioma Studies (95)
- Asbestos Abatement (74)
- Asbestos Bankruptcies (1)
- Asbestos in Products (14)
- Asbestos in Schools (24)
- Asbestos Legislation (58)
- Drug Companies (87)
  - ImClone Systems Incorporated (1)
  - Alfacell (27)
  - Bristol-Myers Squibb (1)
  - CuraGen (1)
  - Eli Lilly (19)
  - Fujirebio Diagnostics, Inc. (9)
  - Genentech (1)
  - Innovive Pharmaceuticals (3)
  - MolMed (1)
  - NeoPharm, Inc. (1)
  - Raptor Pharmaceuticals Corporation (1)
  - Rosetta Genomics (7)
  - Solbec Pharmaceuticals Ltd (1)
  - TopoTarget (1)
  - Zengen, Inc. (1)
- Full Archive (386)
- Libby, MT (15)
- Novel Treatments & Drugs (103)
  - Avastin (3)
  - Carboplatin (ParaplatinÂ®) (8)
  - Cisplatin (Platinol Â®) (12)
  - Coramsine (1)
  - Gemcitabine (1)
  - histone deacetylase inhibitors (1)
  - melanocortin receptors (MCR) subtypes MC1R and MC3R (1)
  - MESOMARK (8)
  - Mesothelioma Blood Test (12)
  - Onconase (ranpirnase) (23)
  - Pemetrexed (Alimta) (28)
  - Raltitrexed (TomudexÂ®) (2)
- Organizations (206)
  - Asbestos Disease Awareness Organization (ADAO) (74)
  - Cancer Monthly (9)
  - Centers for Disease Control (CDC) (4)
  - Environmental Protection Agency (EPA) (67)
  - Environmental Working Group (EWG) (6)
  - Mesothelioma Applied Research Foundation (MARF) (35)
  - NYU Medical Center (1)
- Polio Vaccine – Simian Virus 40 (SV40) (3)
- Trust Funds (10)
Meso News Archives:
- 2012
- 2011
- 2010
- 2009
- 2008
- 2007
- 2006
- 2005
- 2004
- 2003
- 2002
- 2001
- 2000
- 1999
- 1998
You are currently browsing the archives for the Rosetta Genomics category.

Archive for the 'Rosetta Genomics' Category

Tuesday, April 13th, 2010 - microRNAs Shown To Have Powerful Potential as Diagnostic and Prognostic Markers In A Variety Of Cancer Indications

Thursday, February 18th, 2010 - Joint Study by Rosetta Genomics and NYU Langone Medical Center Identifies Single microRNA Biomarker for Prognosis of Mesothelioma Patients

Monday, August 10th, 2009 - Rosetta Genomics and Warnex Medical Laboratories Announce Exclusive Distribution Agreement for Rosetta’s microRNA-based Assays in Canada

Monday, April 13th, 2009 - Prometheus and Rosetta Genomics Announce License and Collaboration Agreement

Monday, December 29th, 2008 - Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) meso

Friday, May 16th, 2008 - Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO)

Monday, April 23rd, 2007 - NYU Medical Center Partners With Rosetta Genomics to Develop a Line of Diagnostic Tools for Lung and Mesothelioma Cancers

Main:

Home | Contact The Mesothelioma Center

Asbestos Diseases:

Malignant Mesothelioma: Pleural, Peritoneal | Diagnosis | Symptoms | Treatment Options | Clinical Trials | Asbestos Lung Cancer | Asbestosis

Asbestos:

About Asbestos | Asbestos in Materials | Products that contain Asbestos

Hope & Help:

Support | Patient Network | Support Groups | Doctors/Specialists

Info & Resources:

Common Questions | News | Web Resources | Site Map

Looking for mesothelioma lawyers? Experienced asbestos attorneys.

Please read our disclaimer. Goldberg, Persky & White, P.C.

Last Updated: January 13, 2012. 06:25:40 pm.